Anna är 52 och på vecka tre av sin GLP-1-behandling. Förut var besöken var fjärde vecka, sedan var tolfte. Emellan dem — tyst.

Nu ser det annorlunda ut. Tisdag morgon i bilen pratar hon in en liten rapport på 90 sekunder. Hon säger att middagen varit tung, att illamåendet har lugnat sig, att hon börjat promenera varje lunch.

Kvällen innan Anna ska till Julia har Julia redan en kort sammanfattning i sin panel. Inte data att gräva i — bara det hon behöver känna till innan de ses.

Julia is a nurse. It is Monday, 08:15. Before Sundvikt, Monday meant 240 patient rows, no triage, no signal. She read the same charts, in the same order, every week.

With Sundvikt, her panel is triaged green, yellow, and red before she sits down. Twelve yellow cases have AI-drafted pre-visit summaries ready — grounded in each patient's phenotype, their protocol, what has changed since the last visit.

She does not pull reports. She does not rebuild context. She spends her day on the conversations only she can have — the medication titration, the social reality, the part that requires being a human in front of another human.

Sundvikt is designed for multi-payer operation from the first patient. Regions, employers, insurers — each sees the outcomes that matter to them, nothing more, nothing less.

Outcomes and treatment-cascade metrics are instrumented before patient one. Retention, weight change, medication adherence, cost per sustained outcome. Not modeled, not projected — observed.

The infrastructure is EU-sovereign. Aleris owns the hardware, the keys, the schema. Patient data never leaves the jurisdiction. GDPR and NIS2 are how we were going to build it anyway.

We do not build pharmacy logistics. We do not build wearables. We do not build gyms or community platforms or mental-health apps. We build the layer where those things meet the clinician and the patient.

If you make GLP-1 medications and you want longitudinal real-world outcomes, we want to talk. If you make CGMs or scales or voice-first interfaces, we want to talk. If you run group programs, movement programs, mental-health programs — we want to talk.

Obesity medicine changed when GLP-1 drugs arrived. The medication works. The system around it — the program, the follow-up, the continuous care — was never built to match.

Sundvikt is a small Aleris module that tries to build that missing layer. It is not a new medication. It is not a chatbot. It is a Postgres database, a few well-lit pages, and a team of clinicians and technologists who spend a lot of time asking what the next month actually looks like for someone on week three of a protocol.